Acquisition of a Q-TOF Mass Spectrometer

描述(由申请人提供)：本申请申请资金用于购买Q-TOF质谱仪，以替换已有18年历史的Bruker Esquire-LC/MS系统的质谱仪组件，该系统是田纳西大学健康科学中心(UTHSC)药学系共享仪器设施的重要组成部分。布鲁克先生的LC/MS系统得到了很好的维护，是支持UTHSC在癌症、肥胖、糖尿病、辐射防护、辐射缓解、细菌感染和炎症疾病领域的广泛小分子药物发现和药物输送计划的主要力量。几种小分子候选药物已获得商业开发许可，其中一种目前处于第三阶段临床试验。然而，目前的质谱仪的年龄导致了近年来越来越频繁的故障。布鲁克在2010年初正式停止了对这类仪器系统的技术支持。修理零件很稀缺，而且变得非常昂贵。拟议的新Q-TOF质谱计将取代Bruker Esquire-LC/MS系统中现在不可靠的质谱计组件。这台功能强大的新型质谱仪将使10多名主要研究人员受益，他们得到了9个R01、1个RC2、1个R33、3个R21和其他支持来源的支持。Q-TOF质谱仪将提供多年可靠的可及性，在MS和MS/MS模式下都具有更高的灵敏度，并能够获得准确的质量，以便更有效地进行结构解析。这一最先进的仪器将通过使用新的小分子及其转化为各种疾病的创新疗法来支持临床前开发中的药物发现。UTHSC坚定致力于支持生物医学研究。药学院将提供25,000美元作为购买新仪器的费用分摊，完全支持一名工作人员维护共享仪器设施，并承担保修期后的所有维护和维修费用，而不收取用户费用。咨询委员会将确保该工具的有效利用，并确保主要用户、其他NIH支持的调查人员、新调查人员和具有早期项目的调查人员有充分的接触机会。 与公共卫生相关：所要求的Q-TOF质谱仪将取代技术有限的Esquire-LC/MS质谱仪，后者已有近20年的历史，并将为目前资助的20个对人类健康重要的项目提供可靠和复杂的支持。这些项目侧重于癌症、肥胖、糖尿病、辐射防护、辐射缓解、细菌感染和炎症性疾病等领域的小分子药物发现和药物输送。

DESCRIPTION (provided by applicant): This application requests funding to acquire a Q-TOF mass spectrometer to replace the mass spectrometer component of an 18-year-old Bruker Esquire-LC/MS system, which is an essential part of the Shared Instrument Facility in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (UTHSC). The Bruker Esquire-LC/MS system has been well maintained and is the work horse supporting extensive small-molecular drug discovery and drug delivery programs at UTHSC in the areas of cancer, obesity, diabetes, radiation protection, radiation mitigation, bacteria inflection, and inflammation diseases. Several small-molecule drug candidates have been licensed for commercial development, including one currently in Phase III clinical trials. However, the age of the current mass spectrometer has resulted in more and more frequent breakdowns in recent years. Bruker officially stopped technical support for this type of instrument system in early 2010. Repair parts are scarce and have become very expensive. The proposed new Q-TOF mass spectrometer will replace the now unreliable mass spectrometer component of the Bruker Esquire-LC/MS system. This powerful new mass spectrometer will benefit more than 10 principal investigators supported by nine R01s, one RC2, one R33, three R21s, and other sources of support. The Q-TOF mass spectrometer will provide years of reliable accessibility, greater sensitivity in both MS and MS/MS modes, and the capability to obtain accurate mass for more efficient structure elucidation. This state-of-the-art instrument wil support drug discovery in preclinical development by using novel small molecules and their translation to innovative therapies for a variety of diseases. UTHSC is strongly committed to supporting biomedical research. The College of Pharmacy will provide $25,000 as a cost share for the purchase of the new instrument, fully support a staff scientist to maintain the Shared Instrument Facility, and assume all future maintenance and repair cost after the warranty period without charging user fees. An advisory committee will ensure effective utilization of the instrument and adequate access by the major users, other NIH-supported investigators, new investigators, and investigators with early-stage projects. PUBLIC HEALTH RELEVANCE: The Q-TOF mass spectrometer requested will replace a technologically limited Esquire-LC/MS mass spectrometer that is nearly two decades old and will provide reliable and sophisticated support for 20 currently funded projects important to human health. These projects focus on small-molecule drug discovery and drug delivery in the areas of cancer, obesity, diabetes, radiation protection, radiation mitigation, bacteria inflection and inflammation diseases.